nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—UGT2B7—Epirubicin—testicular cancer	0.331	0.5	CbGbCtD
Tapentadol—CYP2C19—Ifosfamide—testicular cancer	0.115	0.173	CbGbCtD
Tapentadol—CYP2C9—Ifosfamide—testicular cancer	0.0954	0.144	CbGbCtD
Tapentadol—CYP2C9—Cisplatin—testicular cancer	0.0464	0.07	CbGbCtD
Tapentadol—CYP2D6—Vinblastine—testicular cancer	0.0463	0.0698	CbGbCtD
Tapentadol—CYP2D6—Doxorubicin—testicular cancer	0.0284	0.0429	CbGbCtD
Tapentadol—Hypotension—Cisplatin—testicular cancer	0.000672	0.00199	CcSEcCtD
Tapentadol—Nasopharyngitis—Epirubicin—testicular cancer	0.000671	0.00199	CcSEcCtD
Tapentadol—Hypersensitivity—Dactinomycin—testicular cancer	0.00067	0.00199	CcSEcCtD
Tapentadol—Abdominal discomfort—Methotrexate—testicular cancer	0.000665	0.00197	CcSEcCtD
Tapentadol—Confusional state—Etoposide—testicular cancer	0.000664	0.00197	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.000662	0.00196	CcSEcCtD
Tapentadol—Urticaria—Ifosfamide—testicular cancer	0.000662	0.00196	CcSEcCtD
Tapentadol—Anaphylactic shock—Etoposide—testicular cancer	0.000658	0.00195	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000655	0.00194	CcSEcCtD
Tapentadol—Infection—Etoposide—testicular cancer	0.000654	0.00194	CcSEcCtD
Tapentadol—Ataxia—Doxorubicin—testicular cancer	0.000653	0.00194	CcSEcCtD
Tapentadol—Asthenia—Dactinomycin—testicular cancer	0.000653	0.00193	CcSEcCtD
Tapentadol—Paraesthesia—Cisplatin—testicular cancer	0.000645	0.00191	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Methotrexate—testicular cancer	0.000645	0.00191	CcSEcCtD
Tapentadol—Tachycardia—Etoposide—testicular cancer	0.000643	0.0019	CcSEcCtD
Tapentadol—Dyspnoea—Cisplatin—testicular cancer	0.000641	0.0019	CcSEcCtD
Tapentadol—Skin disorder—Etoposide—testicular cancer	0.000639	0.00189	CcSEcCtD
Tapentadol—Erectile dysfunction—Methotrexate—testicular cancer	0.000639	0.00189	CcSEcCtD
Tapentadol—Hyperhidrosis—Etoposide—testicular cancer	0.000636	0.00189	CcSEcCtD
Tapentadol—Breast disorder—Doxorubicin—testicular cancer	0.000628	0.00186	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.000626	0.00185	CcSEcCtD
Tapentadol—Decreased appetite—Cisplatin—testicular cancer	0.000625	0.00185	CcSEcCtD
Tapentadol—Diarrhoea—Dactinomycin—testicular cancer	0.000622	0.00184	CcSEcCtD
Tapentadol—Nasopharyngitis—Doxorubicin—testicular cancer	0.000621	0.00184	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00062	0.00184	CcSEcCtD
Tapentadol—Vomiting—Bleomycin—testicular cancer	0.00062	0.00184	CcSEcCtD
Tapentadol—Infestation NOS—Methotrexate—testicular cancer	0.000618	0.00183	CcSEcCtD
Tapentadol—Infestation—Methotrexate—testicular cancer	0.000618	0.00183	CcSEcCtD
Tapentadol—Depression—Methotrexate—testicular cancer	0.000617	0.00183	CcSEcCtD
Tapentadol—Hypotension—Etoposide—testicular cancer	0.000615	0.00182	CcSEcCtD
Tapentadol—Rash—Bleomycin—testicular cancer	0.000615	0.00182	CcSEcCtD
Tapentadol—Dermatitis—Bleomycin—testicular cancer	0.000614	0.00182	CcSEcCtD
Tapentadol—Hypersensitivity—Ifosfamide—testicular cancer	0.000614	0.00182	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.000613	0.00182	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Epirubicin—testicular cancer	0.000603	0.00179	CcSEcCtD
Tapentadol—Pollakiuria—Epirubicin—testicular cancer	0.0006	0.00178	CcSEcCtD
Tapentadol—Asthenia—Ifosfamide—testicular cancer	0.000598	0.00177	CcSEcCtD
Tapentadol—Feeling abnormal—Cisplatin—testicular cancer	0.000592	0.00175	CcSEcCtD
Tapentadol—Paraesthesia—Etoposide—testicular cancer	0.000591	0.00175	CcSEcCtD
Tapentadol—Pruritus—Ifosfamide—testicular cancer	0.00059	0.00175	CcSEcCtD
Tapentadol—Weight decreased—Epirubicin—testicular cancer	0.000587	0.00174	CcSEcCtD
Tapentadol—Dyspnoea—Etoposide—testicular cancer	0.000587	0.00174	CcSEcCtD
Tapentadol—Somnolence—Etoposide—testicular cancer	0.000585	0.00173	CcSEcCtD
Tapentadol—Nausea—Bleomycin—testicular cancer	0.000579	0.00172	CcSEcCtD
Tapentadol—Infestation NOS—Epirubicin—testicular cancer	0.000579	0.00171	CcSEcCtD
Tapentadol—Infestation—Epirubicin—testicular cancer	0.000579	0.00171	CcSEcCtD
Tapentadol—Vomiting—Dactinomycin—testicular cancer	0.000578	0.00171	CcSEcCtD
Tapentadol—Rash—Dactinomycin—testicular cancer	0.000574	0.0017	CcSEcCtD
Tapentadol—Decreased appetite—Etoposide—testicular cancer	0.000572	0.0017	CcSEcCtD
Tapentadol—Diarrhoea—Ifosfamide—testicular cancer	0.00057	0.00169	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Etoposide—testicular cancer	0.000568	0.00168	CcSEcCtD
Tapentadol—Fatigue—Etoposide—testicular cancer	0.000568	0.00168	CcSEcCtD
Tapentadol—Constipation—Etoposide—testicular cancer	0.000563	0.00167	CcSEcCtD
Tapentadol—Urinary tract infection—Epirubicin—testicular cancer	0.000562	0.00167	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000558	0.00165	CcSEcCtD
Tapentadol—Pollakiuria—Doxorubicin—testicular cancer	0.000555	0.00164	CcSEcCtD
Tapentadol—Dizziness—Ifosfamide—testicular cancer	0.000551	0.00163	CcSEcCtD
Tapentadol—Urinary tract disorder—Methotrexate—testicular cancer	0.000548	0.00162	CcSEcCtD
Tapentadol—Urethral disorder—Methotrexate—testicular cancer	0.000544	0.00161	CcSEcCtD
Tapentadol—Weight decreased—Doxorubicin—testicular cancer	0.000543	0.00161	CcSEcCtD
Tapentadol—Feeling abnormal—Etoposide—testicular cancer	0.000543	0.00161	CcSEcCtD
Tapentadol—Nausea—Dactinomycin—testicular cancer	0.00054	0.0016	CcSEcCtD
Tapentadol—Infestation NOS—Doxorubicin—testicular cancer	0.000535	0.00159	CcSEcCtD
Tapentadol—Infestation—Doxorubicin—testicular cancer	0.000535	0.00159	CcSEcCtD
Tapentadol—Visual impairment—Methotrexate—testicular cancer	0.000535	0.00158	CcSEcCtD
Tapentadol—Vomiting—Ifosfamide—testicular cancer	0.00053	0.00157	CcSEcCtD
Tapentadol—Hypersensitivity—Cisplatin—testicular cancer	0.000529	0.00157	CcSEcCtD
Tapentadol—Bradycardia—Epirubicin—testicular cancer	0.000529	0.00157	CcSEcCtD
Tapentadol—Rash—Ifosfamide—testicular cancer	0.000526	0.00156	CcSEcCtD
Tapentadol—Dermatitis—Ifosfamide—testicular cancer	0.000525	0.00156	CcSEcCtD
Tapentadol—Urticaria—Etoposide—testicular cancer	0.000523	0.00155	CcSEcCtD
Tapentadol—Urinary tract infection—Doxorubicin—testicular cancer	0.00052	0.00154	CcSEcCtD
Tapentadol—Eye disorder—Methotrexate—testicular cancer	0.000519	0.00154	CcSEcCtD
Tapentadol—Hypoaesthesia—Epirubicin—testicular cancer	0.000517	0.00153	CcSEcCtD
Tapentadol—Asthenia—Cisplatin—testicular cancer	0.000516	0.00153	CcSEcCtD
Tapentadol—Cardiac disorder—Methotrexate—testicular cancer	0.000515	0.00153	CcSEcCtD
Tapentadol—Urinary tract disorder—Epirubicin—testicular cancer	0.000513	0.00152	CcSEcCtD
Tapentadol—Connective tissue disorder—Epirubicin—testicular cancer	0.00051	0.00151	CcSEcCtD
Tapentadol—Urethral disorder—Epirubicin—testicular cancer	0.000509	0.00151	CcSEcCtD
Tapentadol—Angiopathy—Methotrexate—testicular cancer	0.000504	0.00149	CcSEcCtD
Tapentadol—Immune system disorder—Methotrexate—testicular cancer	0.000501	0.00149	CcSEcCtD
Tapentadol—Visual impairment—Epirubicin—testicular cancer	0.000501	0.00148	CcSEcCtD
Tapentadol—Mediastinal disorder—Methotrexate—testicular cancer	0.0005	0.00148	CcSEcCtD
Tapentadol—Chills—Methotrexate—testicular cancer	0.000498	0.00148	CcSEcCtD
Tapentadol—Nausea—Ifosfamide—testicular cancer	0.000495	0.00147	CcSEcCtD
Tapentadol—Diarrhoea—Cisplatin—testicular cancer	0.000492	0.00146	CcSEcCtD
Tapentadol—Bradycardia—Doxorubicin—testicular cancer	0.000489	0.00145	CcSEcCtD
Tapentadol—Mental disorder—Methotrexate—testicular cancer	0.000486	0.00144	CcSEcCtD
Tapentadol—Eye disorder—Epirubicin—testicular cancer	0.000485	0.00144	CcSEcCtD
Tapentadol—Hypersensitivity—Etoposide—testicular cancer	0.000485	0.00144	CcSEcCtD
Tapentadol—Malnutrition—Methotrexate—testicular cancer	0.000483	0.00143	CcSEcCtD
Tapentadol—Cardiac disorder—Epirubicin—testicular cancer	0.000482	0.00143	CcSEcCtD
Tapentadol—Hypoaesthesia—Doxorubicin—testicular cancer	0.000478	0.00142	CcSEcCtD
Tapentadol—Urinary tract disorder—Doxorubicin—testicular cancer	0.000475	0.00141	CcSEcCtD
Tapentadol—Asthenia—Etoposide—testicular cancer	0.000472	0.0014	CcSEcCtD
Tapentadol—Connective tissue disorder—Doxorubicin—testicular cancer	0.000472	0.0014	CcSEcCtD
Tapentadol—Angiopathy—Epirubicin—testicular cancer	0.000471	0.0014	CcSEcCtD
Tapentadol—Urethral disorder—Doxorubicin—testicular cancer	0.000471	0.0014	CcSEcCtD
Tapentadol—Immune system disorder—Epirubicin—testicular cancer	0.000469	0.00139	CcSEcCtD
Tapentadol—Mediastinal disorder—Epirubicin—testicular cancer	0.000468	0.00139	CcSEcCtD
Tapentadol—Chills—Epirubicin—testicular cancer	0.000466	0.00138	CcSEcCtD
Tapentadol—Pruritus—Etoposide—testicular cancer	0.000466	0.00138	CcSEcCtD
Tapentadol—Visual impairment—Doxorubicin—testicular cancer	0.000463	0.00137	CcSEcCtD
Tapentadol—Vomiting—Cisplatin—testicular cancer	0.000457	0.00135	CcSEcCtD
Tapentadol—Vision blurred—Methotrexate—testicular cancer	0.000455	0.00135	CcSEcCtD
Tapentadol—Mental disorder—Epirubicin—testicular cancer	0.000455	0.00135	CcSEcCtD
Tapentadol—Rash—Cisplatin—testicular cancer	0.000453	0.00134	CcSEcCtD
Tapentadol—Dermatitis—Cisplatin—testicular cancer	0.000453	0.00134	CcSEcCtD
Tapentadol—Malnutrition—Epirubicin—testicular cancer	0.000452	0.00134	CcSEcCtD
Tapentadol—Diarrhoea—Etoposide—testicular cancer	0.00045	0.00133	CcSEcCtD
Tapentadol—Eye disorder—Doxorubicin—testicular cancer	0.000449	0.00133	CcSEcCtD
Tapentadol—Cardiac disorder—Doxorubicin—testicular cancer	0.000446	0.00132	CcSEcCtD
Tapentadol—Tension—Epirubicin—testicular cancer	0.000444	0.00131	CcSEcCtD
Tapentadol—Nervousness—Epirubicin—testicular cancer	0.000439	0.0013	CcSEcCtD
Tapentadol—Angiopathy—Doxorubicin—testicular cancer	0.000436	0.00129	CcSEcCtD
Tapentadol—Dizziness—Etoposide—testicular cancer	0.000435	0.00129	CcSEcCtD
Tapentadol—Immune system disorder—Doxorubicin—testicular cancer	0.000434	0.00129	CcSEcCtD
Tapentadol—Vertigo—Methotrexate—testicular cancer	0.000434	0.00129	CcSEcCtD
Tapentadol—Mediastinal disorder—Doxorubicin—testicular cancer	0.000433	0.00128	CcSEcCtD
Tapentadol—Chills—Doxorubicin—testicular cancer	0.000431	0.00128	CcSEcCtD
Tapentadol—Nausea—Cisplatin—testicular cancer	0.000427	0.00126	CcSEcCtD
Tapentadol—Vision blurred—Epirubicin—testicular cancer	0.000426	0.00126	CcSEcCtD
Tapentadol—Cough—Methotrexate—testicular cancer	0.000422	0.00125	CcSEcCtD
Tapentadol—Mental disorder—Doxorubicin—testicular cancer	0.000421	0.00125	CcSEcCtD
Tapentadol—Convulsion—Methotrexate—testicular cancer	0.000419	0.00124	CcSEcCtD
Tapentadol—Vomiting—Etoposide—testicular cancer	0.000419	0.00124	CcSEcCtD
Tapentadol—Malnutrition—Doxorubicin—testicular cancer	0.000418	0.00124	CcSEcCtD
Tapentadol—Agitation—Epirubicin—testicular cancer	0.000416	0.00123	CcSEcCtD
Tapentadol—Rash—Etoposide—testicular cancer	0.000415	0.00123	CcSEcCtD
Tapentadol—Dermatitis—Etoposide—testicular cancer	0.000415	0.00123	CcSEcCtD
Tapentadol—Headache—Etoposide—testicular cancer	0.000412	0.00122	CcSEcCtD
Tapentadol—Arthralgia—Methotrexate—testicular cancer	0.000411	0.00122	CcSEcCtD
Tapentadol—Tension—Doxorubicin—testicular cancer	0.000411	0.00122	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000409	0.00121	CcSEcCtD
Tapentadol—Nervousness—Doxorubicin—testicular cancer	0.000406	0.0012	CcSEcCtD
Tapentadol—Vertigo—Epirubicin—testicular cancer	0.000406	0.0012	CcSEcCtD
Tapentadol—Syncope—Epirubicin—testicular cancer	0.000406	0.0012	CcSEcCtD
Tapentadol—Palpitations—Epirubicin—testicular cancer	0.0004	0.00118	CcSEcCtD
Tapentadol—Confusional state—Methotrexate—testicular cancer	0.000398	0.00118	CcSEcCtD
Tapentadol—Loss of consciousness—Epirubicin—testicular cancer	0.000397	0.00118	CcSEcCtD
Tapentadol—Cough—Epirubicin—testicular cancer	0.000395	0.00117	CcSEcCtD
Tapentadol—Anaphylactic shock—Methotrexate—testicular cancer	0.000394	0.00117	CcSEcCtD
Tapentadol—Vision blurred—Doxorubicin—testicular cancer	0.000394	0.00117	CcSEcCtD
Tapentadol—Convulsion—Epirubicin—testicular cancer	0.000392	0.00116	CcSEcCtD
Tapentadol—Infection—Methotrexate—testicular cancer	0.000392	0.00116	CcSEcCtD
Tapentadol—Nausea—Etoposide—testicular cancer	0.000391	0.00116	CcSEcCtD
Tapentadol—Nervous system disorder—Methotrexate—testicular cancer	0.000387	0.00115	CcSEcCtD
Tapentadol—Arthralgia—Epirubicin—testicular cancer	0.000385	0.00114	CcSEcCtD
Tapentadol—Agitation—Doxorubicin—testicular cancer	0.000385	0.00114	CcSEcCtD
Tapentadol—Anxiety—Epirubicin—testicular cancer	0.000384	0.00114	CcSEcCtD
Tapentadol—Skin disorder—Methotrexate—testicular cancer	0.000383	0.00113	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000382	0.00113	CcSEcCtD
Tapentadol—Hyperhidrosis—Methotrexate—testicular cancer	0.000381	0.00113	CcSEcCtD
Tapentadol—Dry mouth—Epirubicin—testicular cancer	0.000377	0.00112	CcSEcCtD
Tapentadol—Vertigo—Doxorubicin—testicular cancer	0.000376	0.00111	CcSEcCtD
Tapentadol—Syncope—Doxorubicin—testicular cancer	0.000375	0.00111	CcSEcCtD
Tapentadol—Confusional state—Epirubicin—testicular cancer	0.000372	0.0011	CcSEcCtD
Tapentadol—Palpitations—Doxorubicin—testicular cancer	0.00037	0.0011	CcSEcCtD
Tapentadol—Oedema—Epirubicin—testicular cancer	0.000369	0.00109	CcSEcCtD
Tapentadol—Anaphylactic shock—Epirubicin—testicular cancer	0.000369	0.00109	CcSEcCtD
Tapentadol—Hypotension—Methotrexate—testicular cancer	0.000368	0.00109	CcSEcCtD
Tapentadol—Loss of consciousness—Doxorubicin—testicular cancer	0.000368	0.00109	CcSEcCtD
Tapentadol—Infection—Epirubicin—testicular cancer	0.000367	0.00109	CcSEcCtD
Tapentadol—Cough—Doxorubicin—testicular cancer	0.000365	0.00108	CcSEcCtD
Tapentadol—Shock—Epirubicin—testicular cancer	0.000363	0.00108	CcSEcCtD
Tapentadol—Convulsion—Doxorubicin—testicular cancer	0.000363	0.00107	CcSEcCtD
Tapentadol—Nervous system disorder—Epirubicin—testicular cancer	0.000362	0.00107	CcSEcCtD
Tapentadol—Tachycardia—Epirubicin—testicular cancer	0.00036	0.00107	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000359	0.00106	CcSEcCtD
Tapentadol—Skin disorder—Epirubicin—testicular cancer	0.000358	0.00106	CcSEcCtD
Tapentadol—Hyperhidrosis—Epirubicin—testicular cancer	0.000357	0.00106	CcSEcCtD
Tapentadol—Insomnia—Methotrexate—testicular cancer	0.000357	0.00106	CcSEcCtD
Tapentadol—Arthralgia—Doxorubicin—testicular cancer	0.000356	0.00106	CcSEcCtD
Tapentadol—Anxiety—Doxorubicin—testicular cancer	0.000355	0.00105	CcSEcCtD
Tapentadol—Paraesthesia—Methotrexate—testicular cancer	0.000354	0.00105	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000354	0.00105	CcSEcCtD
Tapentadol—Dyspnoea—Methotrexate—testicular cancer	0.000352	0.00104	CcSEcCtD
Tapentadol—Somnolence—Methotrexate—testicular cancer	0.000351	0.00104	CcSEcCtD
Tapentadol—Dry mouth—Doxorubicin—testicular cancer	0.000348	0.00103	CcSEcCtD
Tapentadol—Dyspepsia—Methotrexate—testicular cancer	0.000347	0.00103	CcSEcCtD
Tapentadol—Hypotension—Epirubicin—testicular cancer	0.000345	0.00102	CcSEcCtD
Tapentadol—Confusional state—Doxorubicin—testicular cancer	0.000344	0.00102	CcSEcCtD
Tapentadol—Decreased appetite—Methotrexate—testicular cancer	0.000343	0.00102	CcSEcCtD
Tapentadol—Oedema—Doxorubicin—testicular cancer	0.000341	0.00101	CcSEcCtD
Tapentadol—Anaphylactic shock—Doxorubicin—testicular cancer	0.000341	0.00101	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00034	0.00101	CcSEcCtD
Tapentadol—Fatigue—Methotrexate—testicular cancer	0.00034	0.00101	CcSEcCtD
Tapentadol—Infection—Doxorubicin—testicular cancer	0.000339	0.00101	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000336	0.000996	CcSEcCtD
Tapentadol—Shock—Doxorubicin—testicular cancer	0.000336	0.000995	CcSEcCtD
Tapentadol—Nervous system disorder—Doxorubicin—testicular cancer	0.000335	0.000992	CcSEcCtD
Tapentadol—Insomnia—Epirubicin—testicular cancer	0.000334	0.000989	CcSEcCtD
Tapentadol—Tachycardia—Doxorubicin—testicular cancer	0.000333	0.000987	CcSEcCtD
Tapentadol—Skin disorder—Doxorubicin—testicular cancer	0.000332	0.000983	CcSEcCtD
Tapentadol—Paraesthesia—Epirubicin—testicular cancer	0.000331	0.000982	CcSEcCtD
Tapentadol—Hyperhidrosis—Doxorubicin—testicular cancer	0.00033	0.000978	CcSEcCtD
Tapentadol—Dyspnoea—Epirubicin—testicular cancer	0.000329	0.000975	CcSEcCtD
Tapentadol—Somnolence—Epirubicin—testicular cancer	0.000328	0.000972	CcSEcCtD
Tapentadol—Feeling abnormal—Methotrexate—testicular cancer	0.000325	0.000963	CcSEcCtD
Tapentadol—Dyspepsia—Epirubicin—testicular cancer	0.000325	0.000962	CcSEcCtD
Tapentadol—Decreased appetite—Epirubicin—testicular cancer	0.000321	0.00095	CcSEcCtD
Tapentadol—Hypotension—Doxorubicin—testicular cancer	0.000319	0.000945	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000319	0.000944	CcSEcCtD
Tapentadol—Fatigue—Epirubicin—testicular cancer	0.000318	0.000943	CcSEcCtD
Tapentadol—Constipation—Epirubicin—testicular cancer	0.000316	0.000935	CcSEcCtD
Tapentadol—Urticaria—Methotrexate—testicular cancer	0.000313	0.000928	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000311	0.000922	CcSEcCtD
Tapentadol—Insomnia—Doxorubicin—testicular cancer	0.000309	0.000915	CcSEcCtD
Tapentadol—Paraesthesia—Doxorubicin—testicular cancer	0.000307	0.000908	CcSEcCtD
Tapentadol—Dyspnoea—Doxorubicin—testicular cancer	0.000304	0.000902	CcSEcCtD
Tapentadol—Feeling abnormal—Epirubicin—testicular cancer	0.000304	0.000901	CcSEcCtD
Tapentadol—Somnolence—Doxorubicin—testicular cancer	0.000304	0.000899	CcSEcCtD
Tapentadol—Dyspepsia—Doxorubicin—testicular cancer	0.000301	0.00089	CcSEcCtD
Tapentadol—Decreased appetite—Doxorubicin—testicular cancer	0.000297	0.000879	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000295	0.000873	CcSEcCtD
Tapentadol—Fatigue—Doxorubicin—testicular cancer	0.000294	0.000872	CcSEcCtD
Tapentadol—Urticaria—Epirubicin—testicular cancer	0.000293	0.000869	CcSEcCtD
Tapentadol—Constipation—Doxorubicin—testicular cancer	0.000292	0.000865	CcSEcCtD
Tapentadol—Hypersensitivity—Methotrexate—testicular cancer	0.000291	0.000861	CcSEcCtD
Tapentadol—Asthenia—Methotrexate—testicular cancer	0.000283	0.000838	CcSEcCtD
Tapentadol—Feeling abnormal—Doxorubicin—testicular cancer	0.000281	0.000834	CcSEcCtD
Tapentadol—Pruritus—Methotrexate—testicular cancer	0.000279	0.000827	CcSEcCtD
Tapentadol—Hypersensitivity—Epirubicin—testicular cancer	0.000272	0.000806	CcSEcCtD
Tapentadol—Urticaria—Doxorubicin—testicular cancer	0.000271	0.000804	CcSEcCtD
Tapentadol—Diarrhoea—Methotrexate—testicular cancer	0.00027	0.000799	CcSEcCtD
Tapentadol—Asthenia—Epirubicin—testicular cancer	0.000265	0.000784	CcSEcCtD
Tapentadol—Pruritus—Epirubicin—testicular cancer	0.000261	0.000774	CcSEcCtD
Tapentadol—Dizziness—Methotrexate—testicular cancer	0.000261	0.000773	CcSEcCtD
Tapentadol—Diarrhoea—Epirubicin—testicular cancer	0.000253	0.000748	CcSEcCtD
Tapentadol—Hypersensitivity—Doxorubicin—testicular cancer	0.000252	0.000745	CcSEcCtD
Tapentadol—Vomiting—Methotrexate—testicular cancer	0.000251	0.000743	CcSEcCtD
Tapentadol—Rash—Methotrexate—testicular cancer	0.000249	0.000737	CcSEcCtD
Tapentadol—Dermatitis—Methotrexate—testicular cancer	0.000248	0.000736	CcSEcCtD
Tapentadol—Headache—Methotrexate—testicular cancer	0.000247	0.000732	CcSEcCtD
Tapentadol—Asthenia—Doxorubicin—testicular cancer	0.000245	0.000726	CcSEcCtD
Tapentadol—Dizziness—Epirubicin—testicular cancer	0.000244	0.000723	CcSEcCtD
Tapentadol—Pruritus—Doxorubicin—testicular cancer	0.000242	0.000716	CcSEcCtD
Tapentadol—Vomiting—Epirubicin—testicular cancer	0.000235	0.000695	CcSEcCtD
Tapentadol—Nausea—Methotrexate—testicular cancer	0.000234	0.000694	CcSEcCtD
Tapentadol—Diarrhoea—Doxorubicin—testicular cancer	0.000234	0.000692	CcSEcCtD
Tapentadol—Rash—Epirubicin—testicular cancer	0.000233	0.000689	CcSEcCtD
Tapentadol—Dermatitis—Epirubicin—testicular cancer	0.000232	0.000689	CcSEcCtD
Tapentadol—Headache—Epirubicin—testicular cancer	0.000231	0.000685	CcSEcCtD
Tapentadol—Dizziness—Doxorubicin—testicular cancer	0.000226	0.000669	CcSEcCtD
Tapentadol—Nausea—Epirubicin—testicular cancer	0.000219	0.000649	CcSEcCtD
Tapentadol—Vomiting—Doxorubicin—testicular cancer	0.000217	0.000643	CcSEcCtD
Tapentadol—Rash—Doxorubicin—testicular cancer	0.000215	0.000638	CcSEcCtD
Tapentadol—Dermatitis—Doxorubicin—testicular cancer	0.000215	0.000637	CcSEcCtD
Tapentadol—Headache—Doxorubicin—testicular cancer	0.000214	0.000634	CcSEcCtD
Tapentadol—Nausea—Doxorubicin—testicular cancer	0.000203	0.000601	CcSEcCtD
